Refractory Erdheim-Chester disease

DrugDrug NameDrug Description
DB08881VemurafenibVemurafenib is a BRAF enzyme inhibitor developed by Plexxikon and Genentech for the treatment of late-stage melanoma. The cobasĀ® 4800 BRAF B600 mutation test provided by Roche Molecular Systems is the diagnostic test to confirm eligibility for treatment. FDA approved on August 17, 2011 under the company Hoffmann La Roche.
DrugDrug NamePhaseStatusCount